Real-world data from Israel linked Pfizer’s COVID-19 vaccine to an elevated risk of heart inflammation, researchers said this week.
Israeli scientists found that vaccination likely caused myocarditis, or heart inflammation, in one to five people per 100,000 who wouldn’t have otherwise suffered the condition.
However, they also said that getting COVID-19 was linked to a higher risk—with 11 inflammation events out of 100 attributed to the disease.
Most of the heart inflammation cases post-vaccination were in young males. The 21 people who had myocarditis in the vaccinated group had a median age of 25, and 90.9 percent were men.
“We estimated that the BNT162b2 vaccine resulted in an increased incidence of a few adverse events over a 42-day follow-up period. Although most of these events were mild, some of them, such as myocarditis, could be potentially serious,” they said, referring to the Pfizer-BioNTech vaccine.
A Pfizer spokesperson told The Epoch Times in an email that the company is aware of “…reports of myocarditis and pericarditis, predominantly in male adolescents and young adults, after mRNA COVID-19 vaccination.”
The Pfizer and Moderna vaccines utilize messenger RNA, or mRNA, technology.
The spokesperson noted that the Centers for Disease Control and Prevention describes the heart inflammation as a rare side effect.
The Pfizer vaccine has been found in multiple countries to be associated with an increased risk of heart inflammation, including the United States. U.S. health officials added a warning to the Pfizer and Moderna vaccines in June regarding the higher risk, but have continued recommending them for use, and earlier this week, the Food and Drug Administration (FDA) gave full approval to the Pfizer vaccine.
The Pfizer vaccine, as well as shots offered by Moderna and Johnson & Johnson, had previously been made available to the public through emergency use authorization (EUA) from the FDA. The Moderna and Johnson & Johnson shots are currently still under EUA.
“You need to report separately for boys aged 16-24, who face a vastly higher rate of myocarditis and may not gain much beyond 1 dose,” Prasad, an associate professor in the Department of Epidemiology and Biostatistics at the University of California–San Francisco, wrote on Twitter.